The European Medicines Agency’s CHMP delivered mixed decisions for Sanofi this month: it recommended approval for Wayrilz (rilzabrutinib) in immune thrombocytopenia but issued a negative opinion for Rezurock (belumosudil) as a third‑line treatment for chronic graft‑versus‑host disease. CHMP cited truncated trial data and lack of patient benefit as reasons to rebuff Rezurock, while Wayrilz’s dossier met the committee’s benefit‑risk threshold. Sanofi faces regionally divergent regulatory trajectories that will affect launch sequencing and commercial planning across markets.